The next generation of therapies for adrenocortical cancers
Trends in Endocrinology & Metabolism, ISSN: 1043-2760, Vol: 23, Issue: 7, Page: 343-350
2012
- 19Citations
- 52Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations19
- Citation Indexes19
- 19
- CrossRef18
- Captures52
- Readers52
- 52
Review Description
Adrenocortical carcinoma (ACC) is a rare cancer for which few treatment options have been available. Currently, the best available treatment involves combination chemotherapy with the adrenolytic drug mitotane, although the response rate remains modest. Over the past 10 years there has been renewed interest in the field owing to the recognition that targeted therapies may provide new avenues for effective treatment of this deadly disease. Molecular analyses have revealed specific signaling alterations in ACC, and advances in drug development have generated the tools to block these pathways. Although convincing evidence for the effectiveness of targeted therapies is not currently available, these studies are in progress and should shift the prognosis of this disease in the years to come.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1043276012000537; http://dx.doi.org/10.1016/j.tem.2012.04.001; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84863106031&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/22626690; https://linkinghub.elsevier.com/retrieve/pii/S1043276012000537; https://dx.doi.org/10.1016/j.tem.2012.04.001
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know